Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech, a member of the Roche Group, has selected integrated oncology management company Biologics as a strategic partner to support the launch of its US Food and Drug Administration (FDA) approved oral oncology therapy Zelboraf (vemurafenib).
Subscribe to our email newsletter
Zelboraf is indicated as a treatment for patients with unresectable or metastatic melanoma with BRAFV600E mutation.
Biologics will administer the Patient Partners program, a clinical support service through a primary care model that dedicates an oncology nurse to provide both disease and drug education and support services.
Biologics will also provide adverse event monitoring and reporting, therapy adherence assessments and side effect education and management.
Further, Genentech has selected Biologics’ oncology pharmacy as a strategic channel partner to dispense Zelboraf in the US.